Response of hemopoietic, progenitor, and multipotent mesenchymal stromal cells to administration of ketanserin during pulmonary fibrosis.
We studied the effect of ketanserin on hemopoietic progenitor cells (Lin(-)Sca-1(+)c-Kit(+)CD34- and Lin(-)Sca-1(+)c-Kit(+)CD34(+)), progenitor hemopoietic cells (Lin(-)Sca-1(+)c-kit(+)), and multipotent mesenchymal stromal cells (CD45(-)CD73(+)CD106(+)) in C57Bl/6 mice during pulmonary fibrosis. It was shown that the blocker of 5-HT2A receptors lowers the activity of bleomycin-induced inflammation in the lungs and prevents the infiltration of alveolar interstitium and alveolar ducts by hemopoietic stem and hemopoietic progenitor cells; in this case, they are more numerous in the bone marrow of sick animals. Ketanserin reduces the capacity for self-renewal of lung multipotent mesenchymal stromal cells in the fibrotic phase of the disease and inhibits their differentiation into stromal cell lines (adipocytes, chondrocytes, and fibroblasts) simultaneously with the decrease in the percentage of connective tissue in the lung parenchyma.
E. D. Goldberg Research Institute of Pharmacology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia.
A M
AM
Dygai
E G
EG
Skurikhin
O V
OV
Pershina
I E
IE
Stepanova
E S
ES
Khmelevskaya
N N
NN
Ermakova
A M
AM
Reztsova
V A
VA
Krupin
D V
DV
Reikhart
V E
VE
Goldberg
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000502:physiology; D007650:Ketanserin / Q000494:pharmacology*; D008168:Lung / Q000473:pathology; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000502:physiology; D008810:Mice, Inbred C57BL; D011658:Pulmonary Fibrosis; D012702:Serotonin Antagonists / Q000494:pharmacology*
D012702:Serotonin Antagonists; D007650:Ketanserin